NewEdge Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

NewEdge Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-134	Closed	-$17.7K	–	4198
2025 Q1	$17.7K	Sell	134 -4	-3%	-$498	﹤0.01%	2903
2024 Q4	$11.5K	Hold	138	–	–	﹤0.01%	2990
2024 Q3	$10.1K	Hold	138	–	–	﹤0.01%	2936
2024 Q2	$9.45K	Sell	138 -108	-44%	-$7.49K	﹤0.01%	2874
2024 Q1	$17K	Sell	246 -61	-20%	-$4.19K	﹤0.01%	2682
2023 Q4	$22K	Buy	+307	New	+$17.7K	﹤0.01%	2541
2023 Q1	–	Sell	-30	Closed	-$1.59K	–	4225
2022 Q4	$1.59K	Buy	+30	New	+$1.5K	﹤0.01%	2899

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

NewEdge Advisors's ITCI Position: Q2 2025 in Review

NewEdge Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 134 shares — an estimated $17.7K sold.

NewEdge Advisors first reported a position in ITCI in Q4 2022 and held it in 7 quarters. The position peaked at $22K in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

NewEdge Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 134 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $17.7K.
NewEdge Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 7 quarters.
NewEdge Advisors's Intra-Cellular Therapies Inc. position peaked at $22K in Q4 2023.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.